<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioPharma</title>
	<atom:link href="https://www.worldpharmatoday.com/biopharma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Mon, 31 Aug 2026 08:07:24 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.1</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>BioPharma</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Large Molecule Development Supporting Complex Biologic Drug Programs</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/large-molecule-development-supporting-complex-biologic-drug-programs/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 31 Aug 2026 08:07:24 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/large-molecule-development-supporting-complex-biologic-drug-programs/</guid>

					<description><![CDATA[<p>The pharmaceutical industry is experiencing a profound expansion in the biologic sector, driven by the need for more targeted and effective therapies for chronic diseases. Unlike small molecules, biologics are produced in living systems, which introduces a high degree of complexity in both discovery and manufacturing. This complexity necessitates a rigorous approach to large molecule [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/large-molecule-development-supporting-complex-biologic-drug-programs/">Large Molecule Development Supporting Complex Biologic Drug Programs</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>McKesson to Acquire Precision Medicine Group for $2.25 Billion</title>
		<link>https://www.worldpharmatoday.com/news/mckesson-to-acquire-precision-medicine-group-for-2-25-billion/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 27 Aug 2026 08:36:00 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/mckesson-to-acquire-precision-medicine-group-for-2-25-billion/</guid>

					<description><![CDATA[<p>US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25 billion, a move aimed at strengthening its clinical research and biopharmaceutical commercialisation services. The McKesson acquisition remains subject to customary closing conditions, including regulatory approvals. Once the transaction receives final clearances, Precision Medicine Group will operate within McKesson&#8217;s oncology and multi-speciality [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/mckesson-to-acquire-precision-medicine-group-for-2-25-billion/">McKesson to Acquire Precision Medicine Group for $2.25 Billion</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Biopharmaceutical Fluid Handling Systems Improving Process Efficiency and Product Integrity</title>
		<link>https://www.worldpharmatoday.com/biopharma/biopharmaceutical-fluid-handling-systems-improving-process-efficiency-and-product-integrity/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 25 Aug 2026 13:11:32 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/biopharmaceutical-fluid-handling-systems-improving-process-efficiency-and-product-integrity/</guid>

					<description><![CDATA[<p>The implementation of biopharmaceutical fluid handling systems improving process efficiency and Product Integrity is a foundational requirement for the modern manufacturing of biologics, vaccines, and advanced therapy medicinal products. Unlike traditional chemical synthesis, biopharmaceutical production involves the management of living cells and highly sensitive protein structures that are susceptible to environmental changes and mechanical stress. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/biopharmaceutical-fluid-handling-systems-improving-process-efficiency-and-product-integrity/">Biopharmaceutical Fluid Handling Systems Improving Process Efficiency and Product Integrity</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Targeted Delivery Systems Improving Pharmacological Agent Localization</title>
		<link>https://www.worldpharmatoday.com/biopharma/targeted-delivery-systems-improving-pharmacological-agent-localization/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 24 Aug 2026 12:35:52 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/targeted-delivery-systems-improving-pharmacological-agent-localization/</guid>

					<description><![CDATA[<p>Precision in the delivery of therapeutic compounds remains a primary objective for pharmaceutical scientists seeking to maximize efficacy while minimizing the potential for systemic toxicity. The development of targeted delivery systems improving pharmacological agent localization represents a significant shift in how pharmacological interventions are administered, moving away from broad-spectrum systemic exposure toward highly localized cellular [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/targeted-delivery-systems-improving-pharmacological-agent-localization/">Targeted Delivery Systems Improving Pharmacological Agent Localization</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Lipid Nanoparticle Screening Advancing Oligonucleotide Delivery</title>
		<link>https://www.worldpharmatoday.com/biopharma/lipid-nanoparticle-screening-advancing-oligonucleotide-delivery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 24 Aug 2026 12:28:37 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/lipid-nanoparticle-screening-advancing-oligonucleotide-delivery/</guid>

					<description><![CDATA[<p>The recent success of ribonucleic acid therapeutics has been largely dependent on the development of effective vehicles capable of protecting fragile genetic material from enzymatic degradation while facilitating its entry into target cells. The process of lipid nanoparticle screening advancing oligonucleotide delivery has emerged as a cornerstone of this technological evolution, allowing researchers to systematically [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/lipid-nanoparticle-screening-advancing-oligonucleotide-delivery/">Lipid Nanoparticle Screening Advancing Oligonucleotide Delivery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Data Analytics Improving Bioperformance Prediction for Small Molecules</title>
		<link>https://www.worldpharmatoday.com/biopharma/data-analytics-improving-bioperformance-prediction-for-small-molecules/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 24 Aug 2026 12:20:23 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/data-analytics-improving-bioperformance-prediction-for-small-molecules/</guid>

					<description><![CDATA[<p>Pharmaceutical developers are increasingly integrating advanced computational frameworks to address the high rates of attrition in clinical trials, specifically by refining how candidate molecules interact with biological systems. The current shift toward data analytics improving bioperformance prediction for small molecules allows researchers to simulate human physiological responses with unprecedented precision, moving beyond the limitations of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/data-analytics-improving-bioperformance-prediction-for-small-molecules/">Data Analytics Improving Bioperformance Prediction for Small Molecules</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Lonza Launches Rapid Media Prototyping Service to Accelerate Biopharmaceutical Development</title>
		<link>https://www.worldpharmatoday.com/news/lonza-launches-rapid-media-prototyping-service-to-accelerate-biopharmaceutical-development/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 19 Aug 2026 13:38:24 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/lonza-launches-rapid-media-prototyping-service-to-accelerate-biopharmaceutical-development/</guid>

					<description><![CDATA[<p>Lonza has announced the launch of its Rapid Media Prototyping Service (RaMP) — a solution designed to give biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation, and early development. Delivering Speed and Flexibility in Early Development The new service enables the production of non-GMP powder batches ranging from 1 [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/lonza-launches-rapid-media-prototyping-service-to-accelerate-biopharmaceutical-development/">Lonza Launches Rapid Media Prototyping Service to Accelerate Biopharmaceutical Development</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement</title>
		<link>https://www.worldpharmatoday.com/news/sandoz-expands-global-pipeline-with-multi-product-biosimilar-agreement/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 17 Aug 2026 14:11:23 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/sandoz-expands-global-pipeline-with-multi-product-biosimilar-agreement/</guid>

					<description><![CDATA[<p>Sandoz has entered into a collaboration agreement with Shanghai Henlius Biotech to co-develop a series of new biosimilars across international markets. The milestone-based transaction carries a total consideration of up to $322m, including near-term payments of up to $100.5m associated with initial product candidates. Under the terms of this biosimilar collaboration, Henlius will oversee development [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/sandoz-expands-global-pipeline-with-multi-product-biosimilar-agreement/">Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture</title>
		<link>https://www.worldpharmatoday.com/news/cspc-pharmaceutical-and-astrazeneca-form-biologics-joint-venture/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 06 Aug 2026 12:04:34 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cspc-pharmaceutical-and-astrazeneca-form-biologics-joint-venture/</guid>

					<description><![CDATA[<p>CSPC Pharmaceutical and AstraZeneca have signed a joint venture contract to establish a new-generation production facility in Shijiazhuang, China. The collaboration focuses on the manufacturing and global supply of mutually agreed biologics drug substances, with capital contributions structured at a 51:49 equity ratio in favor of CSPC Pharmaceutical. The agreement remains subject to customary closing [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/cspc-pharmaceutical-and-astrazeneca-form-biologics-joint-venture/">CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Industrial Water Reuse Supporting Biopharma Manufacturing</title>
		<link>https://www.worldpharmatoday.com/biopharma/industrial-water-reuse-supporting-biopharma-manufacturing/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 27 Jul 2026 10:52:39 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/industrial-water-reuse-supporting-biopharma-manufacturing/</guid>

					<description><![CDATA[<p>The biopharmaceutical industry is one of the most water-intensive sectors of the global economy, requiring quantities of high-purity water for media preparation, equipment cleaning, and final product formulation. As global water scarcity increases and regulatory pressure on environmental sustainability intensifies, manufacturers are increasingly turning to circular water strategies. Fluid-handling and treatment equipment supporting biopharma manufacturing [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/industrial-water-reuse-supporting-biopharma-manufacturing/">Industrial Water Reuse Supporting Biopharma Manufacturing</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
